Journal: Genes & Diseases

Article Title: MFAP2 promotes metastasis and drug resistance by regulating epithelial-to-mesenchymal transition through EGFR signaling pathway in colorectal cancer cells

doi: 10.1016/j.gendis.2025.101800

Figure Lengend Snippet: MFAP2 promotes epithelial–mesenchymal transition (EMT) through the EGFR-AKT-STAT3 signaling pathway in colorectal cancer (CRC) cells. (A, B) The top 20 enrichment signaling pathways regulated by MFAP2 knockdown. (C, D) VEGFR2 signaling pathway was enriched in the MFAP2 knockdown cells, shown by Gene Set Enrichment Analysis (GSEA) and essential genes in this enrichment. (E) MFAP2 knockdown affected the EGFR-AKT-STAT3 axis.

Article Snippet: Following blocking with 5% non-fat milk in PBS with 0.02% Tween 20 detergent (PBST) at room temperature for 2 h, the membranes were incubated with primary antibodies, including MFAP2 (Solarbio, China), GAPDH (BBI Co., Ltd., China), epidermal growth factor receptor (EGFR; Proteintech, China), protein kinase B (AKT) (Proteintech), signal transducer and activator of transcription 3 (STAT3) (Proteintech), and vascular endothelial growth factor A (VEGFA) (Proteintech), p-EGFR (Cell Signaling Technology, USA), p-STAT3 (Cell Signaling Technology), and p-AKT ser473 (Cell Signaling Technology) antibodies, at 4 °C overnight.

Techniques: Protein-Protein interactions, Knockdown

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: An innovative treatment for lung cancer using gene-engineered human-induced pluripotent stem cell-derived natural killer cells

doi: 10.1007/s00262-026-04370-7

Figure Lengend Snippet: Effects of eNK cells on the PDX mouse model. a Characterization of J-PDX_E0050. b The tumor mass derived from a patient was maintained in mice, then cut into pieces (approximately 2–3 mm in size), and finally implanted subcutaneously into NOG mice. When the tumors grew to approximately 200 mm 3 , the mice were randomized (day 0). Arrows depict the day of eNK cells administration. c EGFR expression of tumor tissues in J-PDX_E0050-bearing NOG mice. d eNK cells (red arrows) and Cmab (black arrows) were administered three times a week for 3 weeks from day 0 and day 1, respectively. Data are shown as mean ± SD. For all groups, n = 5 except where the number of animals is indicated in parenthesis. *; p < 0.05 vs control (vehicle) (Student t test) PDX, patient-derived xenograft; NOG, NOD/Shi-scid IL-2R gamma (null); EGFR, epidermal growth factor receptor; Cmab, cetuximab. e Representative whole-slide images of immunohistochemistry for human CD45 in tumors harvested on Day 35 (16 days after the last administration). Sections were stained with anti-human CD45 antibody (clone D9M81, Cell Signaling Technology). Whole-slide images were acquired using a Hamamatsu NanoZoomer digital slide scanner (Hamamatsu Photonics, Shizuoka, Japan). Boxes indicate the regions shown at higher magnification. Scale bars, 2.5 mm (upper panels) and 100 µm (lower panels)

Article Snippet: Epidermal growth factor receptor (EGFR) immunostaining using anti-EGFR antibody (clone: D38B1, Cell Signaling) was performed at Mediford Corporation (Tokyo, Japan) (formerly LSI Medience Corporation, Tokyo, Japan).

Techniques: Derivative Assay, Expressing, Control, Immunohistochemistry, Staining